BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16266436)

  • 21. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
    Valle M; Price RW; Nilsson A; Heyes M; Verotta D
    Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid response to structured treatment interruption after virological failure.
    Price RW; Paxinos EE; Grant RM; Drews B; Nilsson A; Hoh R; Hellmann NS; Petropoulos CJ; Deeks SG
    AIDS; 2001 Jul; 15(10):1251-9. PubMed ID: 11426069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
    Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
    Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical factors related to brain structure in HIV: the CHARTER study.
    Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I;
    J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
    Abdulle S; Mellgren A; Brew BJ; Cinque P; Hagberg L; Price RW; Rosengren L; Gisslén M
    J Neurol; 2007 Aug; 254(8):1026-32. PubMed ID: 17420923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.
    Nightingale S; Geretti AM; Beloukas A; Fisher M; Winston A; Else L; Nelson M; Taylor S; Ustianowski A; Ainsworth J; Gilson R; Haddow L; Ong E; Watson V; Leen C; Minton J; Post F; Pirmohamed M; Solomon T; Khoo S
    J Neurovirol; 2016 Dec; 22(6):852-860. PubMed ID: 27194435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
    Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
    Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.
    Cinque P; Bestetti A; Marenzi R; Sala S; Gisslen M; Hagberg L; Price RW
    J Neuroimmunol; 2005 Nov; 168(1-2):154-63. PubMed ID: 16091292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.
    Ekwaru JP; Campbell J; Malamba S; Moore DM; Were W; Mermin J
    J Int AIDS Soc; 2013 Apr; 16(1):17355. PubMed ID: 23547778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
    Foudraine NA; Hoetelmans RM; Lange JM; de Wolf F; van Benthem BH; Maas JJ; Keet IP; Portegies P
    Lancet; 1998 May; 351(9115):1547-51. PubMed ID: 10326538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system.
    Price RW; Deeks SG
    J Neurovirol; 2004; 10 Suppl 1():44-51. PubMed ID: 14982739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.
    Antinori A; Giancola ML; Grisetti S; Soldani F; Alba L; Liuzzi G; Amendola A; Capobianchi M; Tozzi V; Perno CF
    AIDS; 2002 Sep; 16(14):1867-76. PubMed ID: 12351946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
    Gisslén M; Fuchs D; Svennerholm B; Hagberg L
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
    Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
    AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
    Probasco JC; Spudich SS; Critchfield J; Lee E; Lollo N; Deeks SG; Price RW
    Neurology; 2008 Aug; 71(7):521-4. PubMed ID: 18695163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
    Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
    Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.